Panelists discuss how the MOMENTUM trial demonstrated momelotinib’s superiority over danazol in symptomatic anemic myelofibrosis patients, showing significant improvements in symptoms (the primary end point), meaningful spleen volume reduction (SVR25/SVR35), and anemia benefits, with experts noting that the inclusion of a washout period provided clearer evidence of momelotinib’s efficacy profile compared to the SIMPLIFY-2 trial.
Panelists discuss how second-line treatment decisions for myelofibrosis patients failing ruxolitinib can be guided by clinical trial data such as that from SIMPLIFY-2, whereas momelotinib offers comparable spleen control with superior anemia benefits and potential symptom improvement, although experts emphasize the importance of considering a patient’s specific failure pattern and setting appropriate expectations when switching therapies.
Olalekan O Oluwole, MD, MBBS, discusses a study investigating shorter monitoring times post CAR T therapy.
Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, which focused on Black patients with metastatic hormone-sensitive prostate cancer.
Amandeep Salhotra, MD, discusses Orca-T and its evaluation in the phase 3 Precision-T trial in patients with advanced hematologic malignancies.
Panelists discuss how managing myelofibrosis patients with challenging cytopenias involves careful treatment selection, regular monitoring of blood counts, and tailored dose adjustments to balance disease control with the risks of exacerbating hematologic toxicities.
Panelists discuss how selecting and optimizing Janus kinase (JAK) inhibitor therapy in myelofibrosis involves personalizing treatment based on patient risk factors, comorbidities, and preferences while emphasizing regular monitoring to manage adverse effects and improve quality of life.
Jyoti Srivastava, PhD, discusses a study investigating methods to boost inhibitor function in advanced melanoma.
Panelists discuss how frequent phlebotomy requirements—typically more than 4 to 6 times per year—serve as a marker of inadequate disease control in polycythemia vera (PV), prompting consideration of cytoreductive therapy to improve hematologic stability, alleviate symptoms, and reduce thrombotic risk.
Panelists discuss how difficult-to-diagnose cases of chronic graft-vs-host disease (cGVHD) often include pulmonary involvement, gynecological manifestations, and neurological symptoms.
Panelists discuss how the decision to initiate cytoreductive therapy in polycythemia vera (PV) is driven by high-risk features such as age over 60 and thrombotic history, as well as factors like inadequate hematocrit control, symptom burden, and intolerance to phlebotomy, with therapy tailored to individual patient needs and goals.
A panelist discusses how successful management of chronic graft-vs-host disease (cGVHD) requires a multifaceted approach that combines prompt recognition, strategic intervention, and comprehensive supportive care to optimize both disease control and quality of life for transplant survivors.
Panelists discuss how clinicians typically diagnose chronic graft-vs-host disease (cGVHD) based on clinical features rather than biopsies, except in atypical or uncertain cases.
Ahmad Abuhelwa, MD, discusses the significance of a study exploring statin use in patients with chronic lymphocytic leukemia.
A transformative milestone in cancer care has arrived in Central New Jersey with the reopening of the John Theurer Cancer Center at 80 James Street in Edison.
Neal Shore, MD, FACS, discusses sasanlimab and its potential impact for community oncologists when treating patients with high-risk non–muscle invasive bladder cancer.
Jason M. Hafron, MD, discusses IsoPSA, a novel prostate-specific antigen assay for patients with a PSA > 4ng/ml who are facing a decision on prostate biopsy.
Ahmad Abuhelwa, MD, discusses an analysis exploring the connection between statins and better outcomes in patients with CLL and SLL.
Ahmad Abuhelwa, MD, discusses the mechanisms of statins and how they can play a surprisingly beneficial role in patients with chronic lymphocytic leukemia.
Ahmad Tarhini, MD, PhD, provides data into his research looking at inherited genetic variations and genetic ancestry in patients with high-risk melanoma.
Felix Guerrero-Ramos, MD, PhD, discusses the importance of the findings from the SunRISe-1 study of TAR-200 in bladder cancer from the 2025 AUA Annual Meeting.
In interviews with Targeted Oncology, Ronan J. Kelly, MD, MBA, and David Zhen, MD, discuss the CheckMate 649 trial of nivolumab plus ipilimumab and look back on last year's ODAC meeting on its use in PD-L1–negative gastrointestinal cancers.
An expert discusses how addressing unmet needs in early diagnosis, treatment options, and long-term management, alongside exploring targeted therapies, combination approaches, and advancements in stem cell transplantation, holds promise for more effective and less toxic treatments for blastic plasmacytoid dendritic cell neoplasm (BPDCN).
An expert discusses how structuring clear roles, fostering communication, and using technology in the shared-care model between academic and community centers, alongside monitoring blood glucose levels, kidney function, and comorbidities, ensures effective collaboration and safe use of tagraxofusp (TAG) therapy.
An expert discusses how effective use of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm (BPDCN) requires proactive monitoring for capillary leak syndrome, liver toxicity, and myelosuppression, with structured protocols and multidisciplinary coordination—especially in community settings—to ensure early intervention and safe, successful treatment delivery.
An expert discusses how treatment selection in blastic plasmacytoid dendritic cell neoplasm (BPDCN) involves balancing disease-specific targeting and patient fitness, with tagraxofusp remaining the frontline standard due to its efficacy and favorable hematologic recovery, whereas venetoclax/azacitidine may be reserved for less fit patients or relapsed settings.
An expert discusses how effective blastic plasmacytoid dendritic cell neoplasm (BPDCN) management requires early central nervous system (CNS) evaluation and a multidisciplinary approach, with treatment decisions guided by disease burden, patient fitness, and CNS involvement—highlighting the need for systemic tagraxofusp combined with prompt intrathecal therapy to address high-risk features.
Ahmad Tarhini, MD, PhD, discusses inherited genetic variations and genetic ancestry, particularly for patients with high-risk melanoma.